Is There a Future for Neuropeptide Receptor Ligands in the Treatment of Anxiety Disorders?
- 26 March 1999
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 82 (1) , 1-61
- https://doi.org/10.1016/s0163-7258(98)00041-2
Abstract
No abstract availableKeywords
This publication has 257 references indexed in Scilit:
- Alpha-helical CRF blocks differential influence of corticotropin releasing factor (CRF) on appetitive and aversive memory retrieval in ratsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1996
- Isatin is a potent endogenous antagonist of guanylate cyclase-coupled atrial natriuretic peptide receptorsLife Sciences, 1995
- Atrial natriuretic factor inhibits the CRH-stimulated secretion of ACTH and cortisol in manLife Sciences, 1992
- Molecular cloning of the human brain and gastric cholecystokinin receptor: Structure, functional expression and chromosomal localizationBiochemical and Biophysical Research Communications, 1992
- Activating and ‘anxiogenic’ effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasoneLife Sciences, 1986
- ICV-CRH potently affects behavior without altering antinociceptive respondingLife Sciences, 1986
- Neuropeptide Y: Anatomical distribution and possible function in mammalian nervous systemLife Sciences, 1986
- Dexamethasone suppresses pituitary-adrenal but not behavioral effects of centrally administered CRFLife Sciences, 1986
- Corticotrophin releasing factor, grooming and ingestive behaviorLife Sciences, 1982
- Intraventricular corticotropin-releasing factor enhances behavioral effects of noveltyLife Sciences, 1982